Clinician Signature Date Ordered (YYYY-MM-DD)
Transcription
Suite 204 - 2389 Health Sciences Mall, tel: 778.379.2931 Vancouver, British Columbia, V6T 1Z3 fax: 778.379.3567 [email protected] PAT I E N T I N F O R M AT I O N Date of Birth Patient Name (Last, First, Middle Initial) Care Card Number Gender Issuing Province Y Y Y Y- M M - D D Male Unit no. Street Address Postal Code Province City R E F E R R I N G P H Y S I C I A N I N F O R M AT I O N ADDITIONAL PHYSICIAN (S) TO BE COPIED Name Name Institution & Department Institution & Department Street Address Street Address City Female Province Telephone Postal Code Fax City Province Postal Code Telephone Fax Email Email REASON FOR REFERR AL TEST REQUESTED Diagnostic Evaluation CG001 Hotspot Mutation Cancer Panel (NGS) Therapeutic target identification ALK/RET/ROS1 Gene Fusion Assay (NGS) Acquired resistance to drug, specify drug KRAS Mutation Codons 12, 13 (Sanger Sequencing) Other (please explain) S P E C I M E N I N F O R M AT I O N D I A G N O S I S & C L I N I C A L H I S T O RY Organ Involved Complete all applicable sections Hospital Block ID Fixative: 10% Buffered Formalin Diagnosis FFPE Tissue (Block) Additional Information (indicate all that apply) Slides No. sent Other specify Primary tumor Metastasis Scrolls No. thickness No. of tubes Pre-treatment Sample Post-treatment sample Cores No. thickness No. of tubes Chemotherapy drug(s) Previous Molecular Testing PAT H O L O G Y I N F O R M AT I O N Used for block returns H&E slide included Yes No 5um unstained slide included Yes No Pathology report included Yes No Specimen Source: Pathologist name Institution name & address Surgical resection specimen Endoscopic biopsy Fine needle aspiration biopsy Core needle biopsy Surgical biopsy Other, specify: Telephone Email All blocks will be returned to the Pathologist’s address following reporting. Tumor Information: Tumor content (%) L A B U S E O N LY Cellularity (%) Sample receipt date and time Necrosis (%) Initials CG Laboratory number Clinician Signature Date Ordered (YYYY-MM-DD) Ship to: Contextual Genomics, Inc. Suite 204 - 2389 Health Sciences Mall, Vancouver, BC, V6T 1Z3 FFPE Block Core Other Information Scrolls H&E Unstained Slide
Similar documents
APPLICATION FOR REGISTRATION: STUDENT MEDICAL TECHNICIANS/ LABOTORY ASSISTANT Form 53 GTS/ LAS
More information
Liquid Biopsy Market Revenue, Opportunity, Forecast and Value Chain 2016-2026
Liquid biopsy is minimally invasive diagnostic procedure alternative to surgical biopsies. Liquid biopsy helps in collection of a wide range of information about a cancer/tumor through a simple blood sample. The procedure can help in exact detection of mutations in epidermal growth factor receptors in cancers such Non-Hodgkin’s Lymphoma (NSCLC). Furthermore, identification of traces of the cancer’s DNA in the blood could help in administration of precision treatments that could increase the probability of treatment effectiveness. Liquid biopsies are also helpful in residual cancer detection. This minimally invasive method can be performed with 5 milliliters of blood which would detect present state of metastases in various tumors. The liquid biopsy process is witnessing increasing adoption as it is easier to tolerate and much quicker than a surgical biopsy. The method is expected to emerge as a game changer in the field of oncology in the forthcoming years.
More information